Merrimack Pharma

MACK NASDAQ
6.55
-0.02
-0.30%
休市 16:00 08/16 EDT
开盘
6.63
昨收
6.57
最高
6.64
最低
6.49
成交量
1.34万
成交均量(3M)
6.09万
52周最高
7.50
52周最低
3.340
换手率
0.10%
市值
8,744.13万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Merrimack Pharma MACK股票价格,Merrimack Pharma股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.
展开 >

最近浏览

名称
价格
涨跌幅